Key result
Propofol is linked to similar respiratory depression rates as etomidate in critically ill ED patients.
Why the study?
Some authors believe procedural sedation is unsafe in nonintubated, critically ill patients in the emergency department, necessitating safety evaluation in ASA P3 and P4 patients.
Is procedural sedation with propofol or etomidate safe in nonintubated, critically ill (ASA P3/P4) patients in the emergency department?
Observational (n=62)
Is procedural sedation with propofol or etomidate safe in nonintubated, critically ill (ASA P3/P4) patients in the emergency department?
Absolute Event Rate: 61.3% vs 58.1%
Procedural sedation with propofol or etomidate appears safe in nonintubated, critically ill ED patients, with rates of subclinical respiratory depression similar to those seen in noncritically ill patients.
Supports ED sedation safety in nonintubated ASA P3-P4 patients; observational data leaves open need for randomized confirmation.
Objectives: Procedural sedation is routinely performed in the emergency department (ED). However, some authors believe it is unsafe in nonintubated, critically ill patients. The objective of this study was to determine the safety of ED procedural sedation in the American Society of Anesthesiologists (ASA) physical status classification P3 and P4 patients. Methods: This was a prospective observational study of patients undergoing procedural sedation in the ED between August 2002 and December 2003 who were classified as ASA physical status score P3 or P4. Patients received either propofol or etomidate at the discretion of the treating physician before their painful procedure. Doses, vital signs, end-tidal CO2 (ETCO2) by nasal cannulae, and pulse oximetry were recorded. Respiratory depression (RD) was defined as a change from baseline ETCO2 >10 mm Hg, an oxygen saturation of < 90%, or an absent ETCO2 waveform at any time. Results: Sixty-two critically ill, nonintubated patients were enrolled. Thirty-one patients received propofol, and 31 patients received etomidate. No cardiac rhythm abnormalities were detected. RD was seen in 37 of 62 patients (59.7%): 19 of the 31 (61.3%) who received propofol and 18 of the 31 (58.1%) who received etomidate. The mean decrease from baseline systolic blood pressure was 11.3% (95% confidence interval [CI] = 7.3% to 15.5%): 5.0% (95% CI = 3.0% to 8.1%) for those receiving etomidate and 17.1% (95% CI = 9.9% to 24.3%) for those receiving propofol. No adverse events were reported. Conclusions: The rate of subclinical RD detected by these criteria was similar to previous reports for noncritically ill patients. Procedural sedation of nonintubated ASA physical status score P3 and P4 patients in the ED with either propofol or etomidate appears to be safe.
No takes yet. Share an insight, caveat, or question.
Miner et al. (2005) conducted an observational in Critically ill patients requiring procedural sedation (n=62). Propofol vs. Etomidate was evaluated on Respiratory depression (change from baseline ETCO2 >10 mm Hg, oxygen saturation <90%, or absent ETCO2 waveform). Procedural sedation with propofol or etomidate in critically ill ED patients resulted in respiratory depression in 61.3% and 58.1% of patients, respectively, with no adverse events reported.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: